By Iain Gilbert
Date: Tuesday 07 Oct 2025
(Sharecast News) - Cell and gene therapy outfit Oxford Biomedica said on Tuesday that it had agreed to acquire a viral vector manufacturing site in Rockville, Maryland, from ABL for $60m in cash, expanding its US footprint and strengthening its contract development and manufacturing offering.
By Abigail Townsend
Date: Tuesday 23 Sep 2025
(Sharecast News) - Oxford Biomedica reiterated full-year guidance on Tuesday, after the biopharma saw strong demand throughout the first half and trimmed losses.
By Iain Gilbert
Date: Tuesday 26 Aug 2025
(Sharecast News) - Analysts at RBC Capital Markets hiked their target price on gene and cell therapy firm OXB from 800p to 930p on Tuesday following its recent oversubscribed £60m equity funding and revenue guidance reiteration.
| Currency | UK Pounds |
| Share Price | 619.00p |
| Change Today | 0.000p |
| % Change | 0.00 % |
| 52 Week High | 682.00p |
| 52 Week Low | 232.50p |
| Volume | 134,750 |
| Shares Issued | 120.54m |
| Market Cap | £746.14m |
| RiskGrade | 125 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| Strong Buy | 4 |
| Buy | 2 |
| Neutral | 4 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 10 |

| No dividends found |
| Time | Volume / Share Price |
| 16:37 | 1,969 @ 615.00p |
| 16:47 | 1,257 @ 618.81p |
| 16:37 | 5,841 @ 615.00p |
| 16:37 | 1,969 @ 615.00p |
| 16:35 | 24,082 @ 619.00p |
| Chair | Roch Doliveux |
| CEO | Frank Mathias |
| CFO | Lucinda (Lucy) Crabtree |
You are here: research